National Pharmaceutical Pricing Authority

(Published in Part II, Section 3, Sub Section (ii) of the
Gazette of India Extraordinary)

Government of India
Ministry of Chemicals and Fertilizers
Department of Pharmaceuticals
(National Pharmaceuticals Pricing Authority)

New Delhi, the 5^th November, 2013

ORDER

S.O.3383(E) – In exercise of the powers, conferred by paragraphs 5, 11 and 15 of the Drugs (Prices Control) Order, 2013, read with S.O. No. 1394(E) dated the 30th May, 2013 issued by the Government of India in the Ministry of Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority (hereinafter referred as NPPA) hereby fixes the price as specified in column (5) of the table hereto annexed as the retail price, exclusive of local taxes, if any in relation to each of the formulation specified in the corresponding entry in column (2) of the said Table with the strength and unit specified respectively in the corresponding entries in columns (3) and (4) thereof; manufactured/marketed by M/s Torrent Pharmaceuticals Ltd.

Table

Sl. No.	Name of the Schedule Formulation	Strength	Unit	Ceiling Price (Rs.)
(1)	(2)	(3)	(4)	(5)
--	--	Each uncoated bilayered tablets contains	--	--
1	Telmisartan + Metoprolol succinate Tablets (Telday M 50mg)	Telmisartan 40 mg Metoprolol succinate – 47.50 mg eq. to Metoprolol Tartrate – 50 mg (as extended release form)	1 Tablet	8.87

NOTE :

The manufacturer of above mentioned formulation i.e. “new drug” under paragraph 2(u) of the DPCO, 2013 shall fix the retail price as specified in column (5) of the table hereinabove.
The manufacturer may add local taxes only if they have paid actually to the Government on the retail price mentioned in the column (5) of the above table.
The retail price for a pack of the aforesaid formulation shall be arrived at by the concerned manufacturer in accordance with the retail price specified in column (5) of the above table as per provisions contained in paragraph 11 of the DPCO, 2013. The manufacturer shall issue a price list in Form-V as per the paragraph 24 (2) of the DPCO, 2013.
Where concerned manufacturer of aforesaid formulation with dosage or strength or both as specified in the above table, launches a new drug as per paragraph 2 (u) of DPCO,2013 then he shall apply for prior price approval of such new drug to the NPPA in Form I as specified under schedule-II of the DPCO, 2013.
The concerned manufacturer of above said formulation shall furnish a quarterly return to the NPPA, in respect of its production / import and sale in Form-III of schedule-II of the DPCO, 2013. Manufacturer, in case intending to discontinue above said formulation then he shall furnish information to the NPPA, in respect of discontinuation of the production and / or import of above said formulation in Form-IV of schedule-II of the DPCO, 2013 at least six months prior to the indented date of discontinuation.
In case the retail price of aforesaid formulation is not complied as per instant price notification and notes specified hereinabove in this notification, then the concerned manufacturer/marketing company shall be liable to deposit overcharged amount along with the interest thereon under the provisions of the DPCO, 2013 read with the Essential Commodities Act, 1955.
Consequent to the issue of retail price of the aforesaid formulation as specified in column (2) of the above mentioned table in this notification, the price order(s) if any, issued for concerned manufacturer / marketer prior to the above said date of notification, stand withdrawn.

PN/140/8/2013/F

F.No. 8(8)/2013/D.P./NPPA-Div.II

(MANISH GOSWAMI)
Deputy Director
National Pharmaceutical Pricing Authority

Last Page Updated: 24-01-2019

Note :Website Content Managed by National Pharmaceutical Pricing Authority Ministry of Chemicals and Fertilizers, Designed, Developed and Hosted by National Informatics Centre Services Inc.(NICSI)